ImmunoGen Is Rising on Amgen News

ImmunoGen Inc. announced … that Amgen Inc. licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
TradingMarkets